In Vivo Plain X‐Ray Imaging of Cancer Using Perovskite Quantum Dot Scintillators
Source abstract
Abstract
Abstract Real‐time in vivo detection of cancer via attenuation‐based plain X‐ray imaging is proposed to fundamentally overcome the penetration depth limits of current fluorescence‐based imaging techniques. Using cesium lead bromide (CsPbBr3, CPB) quantum dot (QD) scintillators, real‐time X‐ray detection of 5 mm‐sized Panc‐1 cell tumors grown in a mouse is successfully performed. The QDs are rapidly co‐synthesized and double‐encapsulated with silicon dioxide (SiO2) to completely prevent them from being aggregated, decomposed, or released; they are then conjugated with antibodies to target pancreatic cancer. Due to the dramatic X‐ray attenuation, the X‐ray signal from the CPB QDs placed under the 2 cm‐thick tissue is clearly observed, while their fluorescence signal is not detected at all. In in vivo mouse experiments, the injection of a tiny amount (2.8 μg on a QD basis) of the CPB–SiO2@SiO2–Ab nanoparticles gives rise to a bright spot at the location of the tumor. Cell viability assay and histological analysis confirm the biocompatibility and nontoxicity of the nanoparticles.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Perovskite Materials and Applications · Luminescence Properties of Advanced Materials · Quantum Dots Synthesis And Properties
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry Kookmin University Seoul 02707 South Korea
Department of Neurosurgery Brigham and Women's Hospital Harvard Medical School Boston MA 02115 USA
Division of Gastroenterology Department of Internal Medicine The Catholic University of Korea Seoul 06591 South Korea
Funding
National Research Foundation of Korea
References (39)
Show source-provided references
1. 10.3322/caac.2159010.3322/caac.21590 ↗
2. 10.1038/bjc.2015.4910.1038/bjc.2015.49 ↗
3. 10.1089/cbr.2017.237810.1089/cbr.2017.2378 ↗
4. 10.1126/science.112594910.1126/science.1125949 ↗
5. 10.1038/s41598-019-39502-w10.1038/s41598-019-39502-w ↗
6. Davis M. E. · Nat. Rev. Drug Discovery · 2009 · 7 · 239
7. 10.1002/adma.20170635610.1002/adma.201706356 ↗
8. 10.1053/j.semnuclmed.2006.03.00510.1053/j.semnuclmed.2006.03.005 ↗
9. 10.1021/acs.chemrev.5b0014810.1021/acs.chemrev.5b00148 ↗
10. 10.1073/pnas.150852411210.1073/pnas.1508524112 ↗
11. 10.1038/s41551-017-0131-810.1038/s41551-017-0131-8 ↗
12. 10.1117/1.JBO.21.12.12600610.1117/1.JBO.21.12.126006 ↗
13. 10.1038/nphoton.2014.16610.1038/nphoton.2014.166 ↗
14. 10.1039/C8SC01153B10.1039/C8SC01153B ↗
15. 10.1021/acs.chemrev.5b0000810.1021/acs.chemrev.5b00008 ↗
16. 10.1098/rsta.2011.026410.1098/rsta.2011.0264 ↗
17. 10.1038/nature2475510.1038/nature24755 ↗
18. 10.1039/C6CS00616G10.1039/C6CS00616G ↗
19. 10.1158/0008-5472.CAN-13-238710.1158/0008-5472.CAN-13-2387 ↗
20. 10.1016/j.mayocp.2015.07.01110.1016/j.mayocp.2015.07.011 ↗
21. 10.1038/s41586-018-0451-110.1038/s41586-018-0451-1 ↗
22. 10.1038/s41598-017-08843-910.1038/s41598-017-08843-9 ↗
23. 10.1021/acs.chemrev.8b0064410.1021/acs.chemrev.8b00644 ↗
24. 10.1039/C8CS00740C10.1039/C8CS00740C ↗
25. 10.1021/acs.chemmater.7b0047810.1021/acs.chemmater.7b00478 ↗
26. 10.1038/am.2016.16710.1038/am.2016.167 ↗
27. 10.1021/acsnano.6b0761710.1021/acsnano.6b07617 ↗
28. 10.1364/PRJ.39984510.1364/PRJ.399845 ↗
29. 2012 Centers for Disease Control and Prevention Atlanta GA
30. J. H. Hubbell S. M. Seltzer 2004 U.S. Secretary of Commerce Washington DC
31. Allisy‐Roberts P. · 2007
32. Smith S. W. · 1997
33. Li X. ‐P. · Int. J. Clin. Exp. Pathol. · 2015 · 8 · 6724
34. 10.1002/1520-6866(2001)21:1<97::AID-TCM9>3.0.CO;2-O10.1002/1520-6866(2001)21:1<97::AID-TCM9>3.0.CO;2-O ↗
35. 10.1182/blood-2002-10-322910.1182/blood-2002-10-3229 ↗
36. 10.1016/j.ab.2011.05.01810.1016/j.ab.2011.05.018 ↗
37. 10.1038/ncomms1014910.1038/ncomms10149 ↗
38. 10.1080/1537651070166581410.1080/15376510701665814 ↗
39. 10.3390/ijerph705200810.3390/ijerph7052008 ↗